United Therapeutics (NASDAQ:UTHR) PT Raised to $400.00 at Oppenheimer

United Therapeutics (NASDAQ:UTHR) had its price objective upped by Oppenheimer from $375.00 to $400.00 in a research report released on Thursday, Benzinga reports. Oppenheimer currently has an outperform rating on the biotechnology company’s stock.

A number of other equities research analysts have also commented on UTHR. The Goldman Sachs Group raised United Therapeutics from a sell rating to a neutral rating and raised their price target for the stock from $213.00 to $215.00 in a research report on Monday, February 12th. Leerink Partnrs reaffirmed an outperform rating on shares of United Therapeutics in a research report on Monday, February 5th. StockNews.com lowered United Therapeutics from a strong-buy rating to a buy rating in a report on Thursday, April 11th. SVB Leerink assumed coverage on United Therapeutics in a report on Monday, February 5th. They set an outperform rating and a $330.00 price objective for the company. Finally, HC Wainwright restated a buy rating and issued a $300.00 target price on shares of United Therapeutics in a research note on Thursday. One investment analyst has rated the stock with a hold rating and ten have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has a consensus rating of Moderate Buy and a consensus price target of $308.78.

United Therapeutics Stock Up 1.7 %

Shares of NASDAQ:UTHR opened at $262.40 on Thursday. The company has a 50 day moving average price of $236.86 and a two-hundred day moving average price of $229.35. The company has a debt-to-equity ratio of 0.04, a quick ratio of 4.28 and a current ratio of 3.77. The company has a market capitalization of $11.64 billion, a PE ratio of 12.41 and a beta of 0.54. United Therapeutics has a 52 week low of $204.44 and a 52 week high of $262.51.

United Therapeutics (NASDAQ:UTHR) last released its quarterly earnings data on Wednesday, May 1st. The biotechnology company reported $6.17 EPS for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. The business had revenue of $677.70 million during the quarter, compared to analysts’ expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The firm’s quarterly revenue was up 33.7% on a year-over-year basis. During the same quarter in the prior year, the company earned $4.86 EPS. Analysts forecast that United Therapeutics will post 23.88 earnings per share for the current year.

Insider Activity at United Therapeutics

In related news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction dated Thursday, February 15th. The shares were sold at an average price of $215.31, for a total value of $1,291,860.00. Following the transaction, the executive vice president now owns 36,599 shares in the company, valued at approximately $7,880,130.69. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, EVP Paul A. Mahon sold 6,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $215.31, for a total value of $1,291,860.00. Following the transaction, the executive vice president now owns 36,599 shares of the company’s stock, valued at $7,880,130.69. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Christopher Patusky sold 1,680 shares of the business’s stock in a transaction on Friday, February 23rd. The shares were sold at an average price of $224.00, for a total value of $376,320.00. Following the completion of the sale, the director now owns 4 shares of the company’s stock, valued at $896. The disclosure for this sale can be found here. In the last quarter, insiders have sold 141,790 shares of company stock worth $33,572,685. Company insiders own 12.50% of the company’s stock.

Institutional Trading of United Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. lifted its stake in United Therapeutics by 0.4% in the 3rd quarter. Vanguard Group Inc. now owns 4,662,911 shares of the biotechnology company’s stock valued at $1,053,212,000 after purchasing an additional 20,373 shares during the last quarter. Dimensional Fund Advisors LP grew its holdings in United Therapeutics by 1.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 561,950 shares of the biotechnology company’s stock worth $123,566,000 after acquiring an additional 9,962 shares during the last quarter. Norges Bank bought a new position in United Therapeutics during the 4th quarter worth $100,519,000. LSV Asset Management lifted its holdings in United Therapeutics by 1.0% during the 3rd quarter. LSV Asset Management now owns 383,068 shares of the biotechnology company’s stock worth $86,524,000 after buying an additional 3,700 shares during the period. Finally, Charles Schwab Investment Management Inc. grew its position in shares of United Therapeutics by 2.5% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 319,030 shares of the biotechnology company’s stock valued at $70,152,000 after buying an additional 7,723 shares during the last quarter. Institutional investors own 94.08% of the company’s stock.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.